Last month, the United States Senate unanimously passed a measure expected to encourage Americans to take advantage of genetic testing. When signed into law, the Genetic Information Nondiscrimination Act (GINA) will protect individuals against health insurance and employment discrimination based on their genetic information.
The law should ease the concerns of many individuals at a time when access to genetic information is booming. Over 1000 types of genetic tests are currently on the market for single-gene diseases, like cystic fibrosis and hemophilia. And the latest crop of DNA testing services, often sold directly to customers, offer to scan a person's entire genome to determine the likelihood of developing more common conditions like obesity or Alzheimer's disease.
Whole-genome services, launched in the past couple of years, have quickly grabbed headlines and people's imaginations ( Figure 1 ). But beyond novelty, the companies marketing these products claim that knowledge of a person's genetic code will be an important tool for making better decisions about health and lifestyle, and in some cases medical care. And in future, the data and tools these companies are amassing could provide a resource to genetic researchers.
Online Genomes For 2.5 ml of saliva and US$999, 23andMe, a genetics startup company with headquarters in California, delivers genetic information on 60 or so conditions-from type II diabetes to earwax type. Customers also find out about their maternal and paternal ancestry and whether they share common ancestors with Ben Franklin or U2′s frontman Bono. 23andMe and other similar companies-including deCODEMe (an offshoot of deCODE Pharmaceuticals in Iceland, founded by geneticist Kari Stefansson) and California-based Navigenics-determine the pattern of hundreds of thousands of single-nucleotide polymorphisms (SNPs) across a person's genome. Because many SNPs are associated with disease-causing forms of genes, having one SNP versus another signals a higher predisposition for developing certain conditions. 23andMe tests for over 600,000 SNPs and makes the results-both the raw data and their analysis-available to customers through a secure, private website. In the Gene Journals section of the website customers learn about their SNP patterns, or genotypes, and their associations with particular traits expressed as an odds ratio (that is, the odds of someone with that genotype developing a trait compared with the odds for the general population).
Each association is also given a score of 1 to 4 stars depending on the validity of the study it was based on. "Four stars means that it is a really solid study, typically replicated in different populations," says Linda Avey, who with Anne Wojcicki (spouse of Google cofounder Sergey Brin), founded 23andMe in 2006. "This field is rapidly evolving and we wanted to develop a way for our customers to see the process as it unfolds. By developing this way to categorize research discoveries, we hope our customers will come to recognize the caveats as well."
Because so much is still unknown about the relationship between SNPs and most conditions or the best way to calculate risk estimates, the company is careful not to oversell its product. "We explain that it is not a diagnostic test. This is so early in the process," says Avey. in on the multiple genes associated with such complex diseases, but interpreting the results is a daunting challenge. "There might be modifier loci that affect the contribution of different variants. The context of the mutation background is important. And for every condition, it is always a balance between nature and nurture. We may get a handle on nature but it is very difficult to quantify nurture," says James R. Lupski, Cullen professor and vice chair of molecular and human genetics and professor of pediatrics at Baylor College of Medicine. "With genomics we are still in the educational stage. Some people are having fun with the technology. The novelty is there, but the clinical utility is currently not." Even well-established associations, such as the ones between certain SNPs and an individual's ability to metabolize many commonly administered drugs, provide limited medical value. "It is good information to have. If you are a poor metabolizer you should know that," says Julio Licinio, chairman of the department of psychiatry and behavioral sciences at the University of Miami Leonard M. Miller School of Medicine. "But in terms of personal medicine, we don't know how to address this knowledge by adjusting drug dosage. There are no specific guidelines." And whether someone is a fast or slow metabolizer becomes irrelevant if the person does not respond at all to a drug. "The typical result is a specific genetic variant increases by 20% the chance you will respond to this drug, but as far as the individual is concerned you might not have the variant and still respond to the drug. So the result is not a complete guide to treatment," says Licinio.
Changing Behavior
Licinio had himself considered signing up for one of the genome scanning services but in the end decided against it. "I asked myself is anything going to change in my life? I have a history of heart disease and cancer in my family, so I know I cannot drink a lot of alcohol or smoke. I cannot be obese. I have to exercise," he explains. "Will knowing that I have a genetic risk factor change this? Or if I don't have a risk factor will I just become fat and lazy?" Yet, companies that provide these genome services point out that many individuals will benefit from knowing their risk factors. "If you have all the risk alleles for type II diabetes, it does not mean that you will get the disease, but you probably should not become obese and should monitor certain metabolic factors. And you might want to start therapy early if you do develop the disease," says genetic researcher Dietrich Stephan, who cofounded Navigenics with oncologist David Agus in 2006. In collaboration with researchers at the Mayo Clinic in Rochester, Navigenics has begun a study to assess the impact of the information it provides to individuals-the results of which should be available within the year. They hope the data will convince skeptics of the value of whole-genome testing. "We regard genetic information as another medical risk factor. If you have two copies of the ApoE4 allele your relative risk for Alzheimer's disease increases by approximately the same amount as being a heavy smoker predisposes you to lung cancer," says Stephan. "It is just another tool that doctors can use to manage a patient."
For an initial fee of US$2500, Navigenics determines a person's likelihood for developing about 18 common diseases, such as type II diabetes, obesity, Alzheimer's disease, prostate cancer, and glaucoma. (The company does not screen for ancestry or nonmedical conditions.) A team of genetic counselors is available anytime by phone to discuss the results. The firm also has two in-house physicians who help craft the advice given to customers, including preventive strategies to reduce the odds of developing a particular disease. Clients can pay a yearly membership fee of US$250 to continue to receive updates and analyses of their genomes as more research information becomes available.
Pushing the Envelope Further
The genome scans provided by 23andMe and Navigenics yield information about increased risk for common conditions. But SNP technology does not screen for disease-causing mutations in specific genes, such as the BRCA1 and BRCA2 genes involved in breast cancer or the MSH2, MSH6, and MLH1 genes linked to colon cancer. Detecting these so-called Mendelian mutations-the presence or absence of which are thought to be the primary cause of disease-requires sequencing the responsible gene. "SNP analysis is cheaper but it has limitations," says Jorge Conde, president and CEO of the Massachusetts-based company Knome. "Sequencing provides the most useful platform so that is where we started." In November 2007 Knome, founded by Harvard geneticist George Church, announced the launch of the first commercial whole-genome sequencing and analysis service for individuals.
The Knome service-which comes with a US$350,000 pricetag-is more hands on than what others provide. A team from Knome flies out to meet prospective clients, explains the process, and takes blood samples. After sequencing 98% of a person's genome-which includes an estimated 20,000 genesthe company analyzes up to 2000 common and rare conditions. Customers are then brought to Cambridge for a roundtable discussion of the findings. "We walk through the analysis and conclusions and make sure that the individual understands what it all means," says Conde. After the initial consultation the company provides ongoing support by phone or web. And as the results of new research become available, clients will be informed of the implications for their genome sequence data.
The entire sequencing and analysis process currently takes 4 to 6 months. As a result, it will initially be offered to 20 individuals. "This is viewed more as a journey and research project rather than a product delivered in a box," says Conde. At the moment, the only named individuals to have had their complete genome sequenced, and whose results have been published, are Craig Venter and Nobel laureate James Watson.
While genome scanning companies typically claim that they do not provide diagnoses, genome scans are making their way into medical care. Scientists at Baylor College of Medicine in Houston have developed a "chip" for screening Mendelian mutations that lead to conditions that affect people later in life. This chip, the first in a series being devel-oped for different groups of patients, can detect over 3000 mutations in 99 distinct genes involved in diseases such as colon cancer, von Hippel Lindau syndrome, and a familial form of Parkinson's disease. "This is an inexpensive way to screen for common mutations in these genes," says John Belmont, professor of molecular and human genetics and pediatrics at Baylor. "But we will not get 100% of mutations." About half of the known Mendelian disease genes carry mutations that have been observed in more than one family. Taken together, these common mutations account for between 20% and 99% of mutant alleles discovered in those genes.
The array does not screen for SNPs. "As medical geneticists we have more experience with Mendelian disorders and on how to apply this kind of genetic information to medical treatment," says Belmont, adding that the chip array is only being offered at Baylor to ensure that results are followed up with the appropriate tests, genetic counseling, and medical management delivered by Board Certified clinical geneticists and genetic counselors. "SNPs give more nebulous information," Belmont points out.
Too Many Smoking Guns
As genome scanning services become more widely used, some worry that a flurry of incidental genomic findings-a phenomenon Isaac Kohane at the Center of Biomedical Informatics at Harvard Medical School refers to as the incidentalome-will outweigh any potential benefits of the technology.
"If you look at table 3 in the paper reporting Jim Watson's genome, he has a number of mutations associated with disease. If you are homozygous for these alleles, you should have the disease, but Watson doesn't," says Kohane. Part of the reason may be that most variants and disease associations have been found in highly selected groups of people. There is little information about how prevalent such variants are across the general population.
Mutations in the HFE gene, for instance, are known to cause hemochromatosis, an iron uptake disorder that involves cirrhosis of the liver, diabetes, abnormal skin pigmentation, and heart failure. "When a genetic test was applied to 41,000 healthy individuals, 152 were homozygous for the known HFE mutation but only one had any findings consistent with the disease. This suggests a huge false positive rate unless we dramatically reduce the prior estimates for the penetrance of that mutation," says Kohane. "Why would you want to inflict that anxiety on people?" Kohane was one of the founders and is currently a consultant for Corralegen, a company that provides genetic tests to physicians, and sits on the scientific board of Navigenics. Nonetheless, he believes that for the moment genetic tests are of most value to people who have symptoms of a disease, or who have a family history or other risk factors that predispose them to developing the disease. In such cases, the tests can better inform diagnosis and treatment. "I guess I am old school," he says. "I don't think you should do a test unless there is a reason."
Because of the uncertainties of genetic information, Kohane and other experts feel that it should not be provided directly to individuals. "I realize we are practicing medicine in different times. Often I will talk to a family that knows more about a disease than I do. It may be the first time I am encountering the disease but they have done a thorough Internet search," says Lupski. "But there is still an important aspect of clinical interpretation. I would not want to just deliver genetic information directly to patients without some counseling about the limitations of the information and the clinical interpretation of what it may mean for the patient and their family."
A Grand Experiment
Many of the reservations about genomic tests have to do with the fact that this is a new science. The genomes of only two individuals have so far been sequenced, and association studies using SNPs have been performed in relatively small groups of selected individuals. As a result, the information that companies like 23andMe, Navigenics, and Knome are obtaining may contribute to the existing body of knowledge, helping to strengthen the science behind genome scans. The information generated by these companieswhether it is a genome sequence or hundreds of thousands of SNPs-belongs to the customers and is treated as private information. But companies expect that some of their customers will be willing to share portions of their data with researchers. "Right now we are providing a service to individuals. But over time it might provide an opportunity for people studying genetics and genomics to turn to us and our clients," says Conde of Knome.
The surge of genome companies many also be providing a push for the development of the tools needed to interpret genomic data. Steven Brenner, a geneticist at the University of California, Berkeley, is spearheading one of many efforts to amalgamate SNP and other mutation data in a single public database within a framework that enables researchers to interpret the data. "To get information of value you have to read the literature and figure out associations. It is a huge burden to do this," says Brenner. "Right now this is being done by individual companies. But their data is proprietary. There is no way of knowing how reliable it is, when it should be used, for whom it is appropriate." In conjunction with Knome, Brenner hopes to unveil a prototype "Genome Commons Navigator" by this summer at http:// genomecommons.org. "The Navigator is a pipeline which takes as input the Genome Commons database and an individual's genome or genotype information and ultimately yields a report of what is genetically distinctive and interesting," he explains.
The rise of genome scanning services may trigger change in another direction: regulation. "There have been calls for increased oversight of genetic testing for years, but initially it was a small niche market," says Kathy Hudson, director of the Genetics and Public Policy Institute in Washington DC. "People in the business have been opposed to enhanced oversight because it decreases the ability to innovate." But the growing number of genetic tests available and of people using these tests are pushing a "broadening consensus among industry labs, medical communities and consumers that there is a need for regulation," she says. Such regulation could take the form of enforcement of the U.S. Federal Trade Commission's authority to prohibit misleading advertising claims with respect to genetic tests. It may also include a publicly available registry of companies that offer genetic tests and oversight of the tests' accuracy and reliability by the U.S. Food and Drug Administration.
The possibilities and pitfalls of genomic scans will become clear with time. But for now 23andMe and other companies are forging ahead with their vision. "When you branch out into something new there is always discussion about the pros and cons. Right now we see more pros in getting the information out to people. We are doing it in a really responsible way and putting the information in proper context," says Avey of 23andMe. "It is a grand experiment but I think we are doing it in a way that will benefit people in the end."
